Anhui Kedgene Biotechnology

Main focus: Next generation T cell-based therapies

Company stage: Clinical

Diseases: Solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Anhui, China

Website: https://www.ankebio.com/english/index.php

Anhui Kedgene Biotechnology develops next generation T cell-based therapies for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimise efficacy and safety.

Anhui Kedgene Biotechnology Co.,Ltd

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CRISPR Unlocks Sweeter Tomatoes Without Yield Loss

Carbon

Nov. 19, 2024

Chinese scientists have achieved a significant advance in tomato agriculture by leveraging CRISPR–Cas9 to enhance sweetness without yield loss. The...

Tackling Antibiotic-Resistant Staphylococcus...

CMN Interview

Nov. 18, 2024

Researchers in Japan have used phagemids for the delivery of CRISPR components to bacteriophage, selectively killing multi-drug resistant bacteria in...

CMN Weekly (15 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 15, 2024

Some of the best links we picked up around the internet

CRISPR Screens Identify Vital lncRNAs

CMN Briefs

Nov. 12, 2024

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

CMN Weekly (8 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 8, 2024

Some of the best links we picked up around the internet

Researchers Report Fewer Large DNA Deletions After...

CMN Briefs

Nov. 7, 2024

Researchers in Korea report that large DNA deletions occur during DNA repair at a much lower frequency for base editors and prime editors than for...